Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

In addition to Wegovy, incretin mimetics FDA-approved for ... Research and Manufacturers of America, condemned the ad for misleading consumers about the safety and effectiveness of the compounded ...

reads text in the print ad, above a needle and vial labeled compounded semaglutide. “Bottom line: If the label doesn’t say Wegovy® (semaglutide) or Ozempic® (semaglutide), it’s not FDA ...

“Novo Nordisk is warning consumers about the significant dangers of reaching for illegitimate compounded ‘semaglutide’ drugs, which have been shown to contain impurities and ingredients ...

TV remained the largest medium till 2021 but 2022 onwards its ad ex share started dropping. From 34% in 2022, it dropped by one percent each year till 2024. Among advertisers, the Fast-Moving ...

Mucinex knocked Vicks off the top spot for monthly TV ad impressions as pharma brands generated significant coverage from ...

Novo Nordisk, the Fortune 500 Europe company behind weight-loss injection Wegovy (semaglutide), responded Monday with a print ad of its own. “Do you really know what you’re injecting into your body?” ...